Testing a communication aid tool for people with Parkinson's disease during doctor visits
Tests a new communication aid during visits with doctors in adults with Parkinson's disease.
Key facts
- Who runs it
- University Hospital, Lille
- Where
- Lille, FranceSee the site
- Trial code
- Registry title
- Evaluation of a New Communication Aid Tool to Favor Global Patient Centered Care
- Status
- Recruiting
- People taking part
- 120 people, planned
- Started
- 21 Jul 2020
- Expected to end
- Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Consulting with PARKINSUN as communication aid-tool
- Consulting without PARKINSUN as communication aid-tool
- Record updated
- 23 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Parkinson's disease at any stage. It tests a communication tool used during visits to the family doctor and the neurologist.
- Age
- 18 to 90 years
- Sex
- Men and women
- Disease stage
- Parkinson's disease, all stages
Main reasons for not taking part
- Severe long-term neurological, mental or psychiatric illness
- Memory or thinking problems that affect independence (MOCA score of 22 or less)
- Not covered by a social security scheme
- Under legal guardianship
- Not fluent in French
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Adult men and women with all stages of PD
- Without severe chronic neurological or mental or psychiatric pathology
- Absence of cognitive impairment affecting autonomy (MDS criteria of dementia and MOCA > 22)
- able to come (alone or accompanied) to consultation
- Affiliate or beneficiary of a social security scheme
- Subject having signed informed consent
- Patient willing to comply with all procedures of the study and its duration
Who cannot take part
- Administrative reasons: impossibility of receiving informed information, inability to participate in the whole study, absence of coverage by the social security system, refusal to sign consent
- Subject under tutelage or curtailer
- Subject not fluent in the French language to understand the instructions necessary to carry out the cognitive tests
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Where in France
- Hopital Roger Salengro, CHU LilleLille, FranceContact: David Devos, MD,PhDTaking people
About the trial
What the trial wants to find out
PARKINSUN is a new communication aid tool, expected to favor global patient centered care for PD patients during consultation with GPs and neurologists. Two groups of patients will be randomized to use or not PARKINSUN when they consult their physicians every 3 months during 7 months.
The 2 groups in the trial
- consultation with ParkinsunTreatment being tested
Treatment: Consulting with PARKINSUN as communication aid-tool
- consultation as usual without ParkinsunExisting treatment, for comparison
Treatment: Consulting without PARKINSUN as communication aid-tool
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Optimizing PD Patient's Health Pathways: Favoring Global, Patient Centered Care by a New Communication Aid Tool PARKINSUN
- Plain-language title
- Testing a communication aid tool for people with Parkinson's disease during doctor visitsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT04179695, who can take part
- Record updated
- 23 December 2025